Small Hospitals
Market Cap
₹6,236 ₹6,236 Cr.
P/E
81.16
PEG
2.50
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive only if planned treatment-volume growth converts from new and acquired capacity; capacity additions alone do not create revenue in this fixed-capacity business.

Bull path depends on a faster treatment-volume ramp combined with a stronger revenue-per-treatment mix, while bear path is triggered by treatment-volume underperformance alongside stagnant revenue per treatment.

Key revision triggers to watch include quarterly treatment growth, revenue per treatment, clinic additions, and the Andhra Pradesh PPP renewal outcome.

  • Nephrocare Health
  • Narayana Hrudayalay.
  • Jupiter Life Line

FAQs on Nephrocare Health Services Ltd. Shareprice

There is not enough historical data for the companies share price.

Nephrocare Health is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Nephrocare Health is 84.68, while 3 year average PE is 84.62.
Also latest EV/EBITDA of Nephrocare Health is 27.75 while 3yr average is 30.73.

Growth Table

  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Balance Sheet

  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Cash Flow

  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Quarterly Results

  • Nephrocare Health Services Ltd.
  • Narayana Hrudayalay.
  • Jupiter Life Line

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Nephrocare Health Services Ltd. Financials

Balance sheet of Nephrocare Health is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Nephrocare Health is decreasing.
Latest net debt of Nephrocare Health is -₹487.15 Crs as of Mar-26.
This is less than Mar-25 when it was -₹83.99 Crs.

Yes, profit is increasing.
The profit of Nephrocare Health is ₹125 Crs for TTM, ₹76.84 Crs for Mar 2026 and ₹67.1 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Nephrocare Health latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech